The FDA recently approved a new medication called Veozah (fezolinetant) for the treatment of moderate to severe hot flashes in menopausal women. Hot flashes are characterized by sudden waves of intense heat, followed by sweating and sometimes chills. Veozah is an oral medication that works by blocking specific receptors, called neurokinin 3 (NK3) receptors, in the central nervous system. These receptors play a role in regulating body temperature.

The drug is classified as an NK3 receptor antagonist, which means it binds to and blocks the activity of NK3 receptors. In two phase 3 clinical trials, Veozah effectively reduced hot flashes. However, some reported side effects of the medication include diarrhea, insomnia, abdominal pain, back pain, hot flashes, and elevated liver transaminases.

Due to the potential for liver injury, Veozah carries a warning, and individuals are advised to undergo blood tests to assess their liver function before starting the medication and at three, six, and nine months after initiating treatment. It is important to note that Veozah is not suitable for individuals taking CYP1A2 inhibitors, as well as those with liver problems or kidney disease.

The recommended dosage of Veozah is one 45mg pill to be taken once a day, with or without food. Janet Maynard, M.D., director of the FDA's Office of Rare Diseases, Pediatrics, Urologic, and Reproductive Medicine, emphasizes the significance of this new treatment option, stating that menopausal hot flashes can have a serious impact on women's quality of life, and Veozah provides a safe and effective alternative for managing this symptom.